DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

DIGITAL CONTENT

2 NEWS #PharmaBuzz

media
2 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

2DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Bal101553, Bal-101553, Lisavanbulin [inn], Lisavanbulin [usan], 1263384-43-5, 5pt0qp06x5

Molecular Formula

C₂₆H₂₉N₉O₃

Molecular Weight

515.6 g/mol

InChI Key

NIPZLALJRAHABJ-IBGZPJMESA-N

FDA UNII

5PT0QP06X5

Lisavanbulin is an orally available, highly water-soluble lysine prodrug of the synthetic small molecule BAL27862 with potential antitumor activity. Upon administration of lisavanbulin and conversion into the active form BAL27862, this agent binds to tubulin at a site distinct from the vinca-alkaloid-binding site, and prevents tubulin polymerization and destabilizes microtubules, ultimately leading to cell cycle arrest, blockage of cell division and an induction of cell death in cancer cells.

1 2D Structure

Lisavanbulin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2S)-2,6-diamino-N-[4-[2-[2-[4-(2-cyanoethylamino)-1,2,5-oxadiazol-3-yl]benzimidazol-1-yl]acetyl]phenyl]hexanamide

2.1.2 InChI

InChI=1S/C26H29N9O3/c27-13-4-3-6-19(29)26(37)31-18-11-9-17(10-12-18)22(36)16-35-21-8-2-1-7-20(21)32-25(35)23-24(34-38-33-23)30-15-5-14-28/h1-2,7-12,19H,3-6,13,15-16,27,29H2,(H,30,34)(H,31,37)/t19-/m0/s1

2.1.3 InChI Key

NIPZLALJRAHABJ-IBGZPJMESA-N

2.1.4 Canonical SMILES

C1=CC=C2C(=C1)N=C(N2CC(=O)C3=CC=C(C=C3)NC(=O)C(CCCCN)N)C4=NON=C4NCCC#N

2.1.5 Isomeric SMILES

C1=CC=C2C(=C1)N=C(N2CC(=O)C3=CC=C(C=C3)NC(=O)[C@H](CCCCN)N)C4=NON=C4NCCC#N

2.2 Other Identifiers

2.2.1 UNII

5PT0QP06X5

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (2s)-2,6-diamino-n-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1h-benzimidazol-1-yl)acetyl)phenyl)hexanamide

2. Bal101553

2.3.2 Depositor-Supplied Synonyms

1. Bal101553

2. Bal-101553

3. Lisavanbulin [inn]

4. Lisavanbulin [usan]

5. 1263384-43-5

6. 5pt0qp06x5

7. Microtubule-targeted Agent Bal101553

8. (2s)-2,6-diamino-n-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1h-benzimidazol-1-yl)acetyl)phenyl)hexanamide

9. Hexanamide, 2,6-diamino-n-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1h-benzimidazol-1-yl)acetyl)phenyl)-, (2s)-

10. Lisavanbulin (usan/inn)

11. Lisavanbulin [usan:inn]

12. Unii-5pt0qp06x5

13. Lisavanbulin [who-dd]

14. Schembl1160313

15. Chembl4297595

16. Glxc-25728

17. Ex-a4306

18. Nsc764608

19. Nsc789724

20. Who 10401

21. Bal 101553

22. Db15224

23. Nsc-764608

24. Nsc-789724

25. D11494

26. Q27262705

2.4 Create Date

2010-05-03

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₉N₉O₃
Molecular Weight	515.6 g/mol
XLogP3	1.5
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	13
Exact Mass	515.23933582 g/mol
Monoisotopic Mass	515.23933582 g/mol
Topological Polar Surface Area	191 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	828
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Immune Checkpoint Inhibitors

Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. (See all compounds classified as Immune Checkpoint Inhibitors.)

Drugs in Development